Last updated on August 2019

A Phase 1b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Brief description of study

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.


Clinical Study Identifier: TX219139

Find a site near you

Start Over

Emory University - Winship Cancer Center

Located in Atlanta, Georgia United States
  Connect »

The University of Arizona Cancer Center

Located in Tucson, Arizona United States
  Connect »

Ochsner Clinic Foundation

Located in New Orleans, Louisiana United States
  Connect »